Base de dados : MEDLINE
Pesquisa : D02.065.589.099.750.750.050 [Categoria DeCS]
Referências encontradas : 12668 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1267 ir para página                         

  1 / 12668 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455806
[Au] Autor:Islas-García I; Romo-Gómez C; de María Cuervo-López F
[Ad] Endereço:Área Académica de Química, Universidad Autónoma del Estado de Hidalgo, Carr. Pachuca-Tulancingo Km. 4.5, Mineral de la Reforma, 42184, Hidalgo, Mexico.
[Ti] Título:Ampicillin Mineralization by Denitrifying Process: Kinetic and Metabolic Effects.
[So] Source:Appl Biochem Biotechnol;183(3):1049-1061, 2017 Nov.
[Is] ISSN:1559-0291
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The impact of the antibiotic ampicillin (AMP) on the metabolic and kinetics of denitrification process as well as the sludge ability for oxidizing it was evaluated in batch assays. Denitrifying reference assays with acetate-C and nitrate-N (C/N ratio of 1.1) were conducted for establishing the metabolic and kinetic performance of the denitrifying sludge. Assays amended with 10 mg AMP-C L were also performed. In reference assays, acetate and nitrate consumption efficiencies of 100% with a total conversion to HCO and N were achieved within 1.5 h. When 10 mg AMP-C L was added, total and simultaneous consumption of nitrate-N, acetate-C, and AMP-C was achieved within 12 h. The substrates were completely reduced to N and oxidized to HCO , respectively. No nitrite-N was registered at the end of culture. AMP caused a reversible inhibitory effect on specific nitrate and acetate consumption and N production rates. Complete consumption and mineralization of AMP associated to nitrate reduction to N were achieved. This work provides the first evidences on the metabolic and kinetic performance of a denitrifying sludge exposed to AMP. These results might be considered for proposing useful wastewater treatments where ß-Lactam antibiotics can be present.
[Mh] Termos MeSH primário: Ampicilina/metabolismo
Ampicilina/farmacologia
Antibacterianos/metabolismo
Antibacterianos/farmacologia
Desnitrificação/efeitos dos fármacos
Minerais/metabolismo
Esgotos
[Mh] Termos MeSH secundário: Acetatos/metabolismo
Relação Dose-Resposta a Droga
Cinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetates); 0 (Anti-Bacterial Agents); 0 (Minerals); 0 (Sewage); 7C782967RD (Ampicillin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE
[do] DOI:10.1007/s12010-017-2483-7


  2 / 12668 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28804111
[Au] Autor:Shimozono K; Hayashi Y; Nishinaka T; Kobayashi S
[Ad] Endereço:Department of Internal Medicine, Otemachi Hospital.
[Ti] Título:An adult case of group A streptococcus meningitis associated with steroid-responsive meningoencephalitis.
[So] Source:Rinsho Shinkeigaku;57(9):499-503, 2017 09 30.
[Is] ISSN:1882-0654
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:A previously healthy 80-year-old woman presented to our service in a comatose state. On examination the patient had fever and neck stiffness. Laboratory investigation showed polymorphonuclear pleocytosis in cerebro-spinal fluid (CSF). These findings prompted us to a diagnosis of bacterial or viral meningitis and combination therapy consisting of ceftriaxone, vancomycin and acyclovir was started immediately. Two days later, culture of blood yielded Streptococcus pyogenes (group A streptococcus; GAS). The antibiotic therapy was converted to intravenous ampicillin for 14 days. Fever resolved quickly, however, somnolence persisted. Fluid attenuated inversion recovery image of the brain, taken on the day 29, showed focal hyperintense lesions on the right subcortical area in the temporal and parietal lobes. Three times repeated intravenous steroid pulse therapy (methylprednisolone 1,000 mg/day, 3 days) resulted in complete improvement of her consciousness disturbance. We considered the present case to be a steroid-responsive meningoencephalitis caused by GAS infection.
[Mh] Termos MeSH primário: Ampicilina/administração & dosagem
Antibacterianos/administração & dosagem
Meningites Bacterianas/complicações
Meningites Bacterianas/tratamento farmacológico
Meningoencefalite/complicações
Meningoencefalite/tratamento farmacológico
Metilprednisolona/administração & dosagem
Infecções Estreptocócicas/complicações
Infecções Estreptocócicas/tratamento farmacológico
Streptococcus pyogenes/isolamento & purificação
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Esquema de Medicação
Feminino
Seres Humanos
Imagem por Ressonância Magnética
Meningites Bacterianas/diagnóstico por imagem
Meningoencefalite/diagnóstico por imagem
Pulsoterapia
Infecções Estreptocócicas/diagnóstico por imagem
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 7C782967RD (Ampicillin); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE
[do] DOI:10.5692/clinicalneurol.cn-001022


  3 / 12668 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28759625
[Au] Autor:Upadhyay K; Hiregoudar B; Meals E; English BK; Talati AJ
[Ad] Endereço:Children's Foundation Research Center at Le Bonheur Children's Hospital; University of Tennessee Health Science Center, Memphis, TN, United States of America.
[Ti] Título:Combination therapy with ampicillin and azithromycin improved outcomes in a mouse model of group B streptococcal sepsis.
[So] Source:PLoS One;12(7):e0182023, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Evidence suggests that ß-lactam monotherapy of streptococcal infections may incite stronger inflammation and is inferior to combination therapy with macrolides. We hypothesized that use of macrolides alone or in combination with a ß-lactam for group B streptococcal (GBS) sepsis would improve outcomes by reducing inflammation. METHODS: TNF-α was measured from supernatants of RAW 264.7 cells stimulated with GBS isolates, in presence of four treatment regimens: ampicillin alone, azithromycin alone, or combination of azithromycin plus ampicillin. Mouse model of GBS sepsis was developed and treated with same four regimens. Clinical sepsis scores were monitored; serum cytokines (TNF-α, IL-6, IL-10) and chemokines (MIP-1α) were measured at the end. RESULTS: GBS isolates exposed to azithromycin or combination (compared to ampicillin alone) stimulated less TNF production in vitro. In the murine sepsis model, mortality was lower along with decreased sepsis scores in mice treated with combination therapy. Mean serum IL-6 was lower in mice treated with azithromycin alone (66±52 pg/ml) or combination of ampicillin plus azithromycin (52±22 pg/ml) compared to ampicillin alone (260±160 pg/ml) (p<0.005). CONCLUSIONS: Combination therapy of ampicillin+azithromycin improved outcomes in a murine GBS sepsis model; this therapeutic approach deserves additional study.
[Mh] Termos MeSH primário: Ampicilina/uso terapêutico
Antibacterianos/uso terapêutico
Azitromicina/uso terapêutico
Sepse/tratamento farmacológico
Infecções Estreptocócicas/tratamento farmacológico
[Mh] Termos MeSH secundário: Ampicilina/administração & dosagem
Animais
Antibacterianos/administração & dosagem
Azitromicina/administração & dosagem
Linhagem Celular
Citocinas/sangue
Quimioterapia Combinada
Feminino
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Cytokines); 7C782967RD (Ampicillin); 83905-01-5 (Azithromycin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182023


  4 / 12668 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28693665
[Au] Autor:Ngbede EO; Raji MA; Kwanashie CN; Kwaga JKP; Adikwu AA; Maurice NA; Adamu AM
[Ad] Endereço:2​Department of Veterinary Microbiology, Ahmadu Bello University, Zaria, Kaduna State, Nigeria 1​Department of Veterinary Pathology & Microbiology, University of Agriculture Makurdi, Benue State, Nigeria.
[Ti] Título:Characterization of high level ampicillin- and aminoglycoside-resistant enterococci isolated from non-hospital sources.
[So] Source:J Med Microbiol;66(7):1027-1032, 2017 Jul.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: High level ampicillin- and aminoglycoside-resistant enterococci are being increasingly reported from non-hospital sources. This study was carried out to characterize these strains from non-hospital sources in Nigeria. METHODOLOGY: A collection of Enterococcus faecium isolated from vegetables, soil, farm animals and manure and observed to be resistant to ampicillin (n=63) and gentamicin (n=37) discs, were screened for resistance to high levels of ampicillin and aminoglycoside using E-test strips. Putative high level ampicillin- and aminoglycoside-resistant strains were screened for pbp5 and aminoglycoside modifying enzyme genes, respectively, by PCR. The C-terminal region of the amplified pbp5 gene was also sequenced. RESULTS: Five (5/63) and thirty-five (35/37) of the ampicillin- and aminoglycoside-resistant strains were identified as high level ampicillin- and aminoglycoside-resistant E. faecium strains, respectively, based on the MIC results. The amplified pbp5 gene from the high level ampicillin-resistant isolates displayed 96-99 % nucleotide sequence similarity with the reference strains and three novel insertions (500Glu→Leu, 502Asp→Arg and 614Ile→Phe) in the amino acid sequence. Aminoglycoside modifying enzyme genes aac(6')-Ie-aph(2″) (100 %), aph(2')-Ic (88.8 %), aph(3')-IIIa (90 %) and ant(4')-Ia (40 %) were detected among the high level aminoglycoside-resistant isolates. CONCLUSION: This is the first report on the characterization of high level ampicillin- and aminoglycoside-resistant Enterococcus faecium among animals and vegetables in Nigeria. The results show that non-hospital sources can constitute a reservoir for potential dissemination of these strains and genes to humans via the food chain or by direct contact.
[Mh] Termos MeSH primário: Aminoglicosídeos/farmacologia
Ampicilina/farmacologia
Antibacterianos/farmacologia
Farmacorresistência Bacteriana
Enterococcus faecium/efeitos dos fármacos
Microbiologia Ambiental
Infecções por Bactérias Gram-Positivas/veterinária
[Mh] Termos MeSH secundário: Animais
Testes de Sensibilidade a Antimicrobianos por Disco-Difusão
Enterococcus faecium/isolamento & purificação
Genes Bacterianos
Infecções por Bactérias Gram-Positivas/microbiologia
Nigéria
Reação em Cadeia da Polimerase
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminoglycosides); 0 (Anti-Bacterial Agents); 7C782967RD (Ampicillin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000518


  5 / 12668 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28658507
[Au] Autor:Kelly LE; Shivananda S; Murthy P; Srinivasjois R; Shah PS
[Ad] Endereço:Department of Paediatrics, University of Toronto Mount Sinai Hospital, Toronto, Canada.
[Ti] Título:Antibiotics for neonates born through meconium-stained amniotic fluid.
[So] Source:Cochrane Database Syst Rev;6:CD006183, 2017 06 28.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Approximately 1 in 10 pregnancies is affected by meconium passage at delivery, which can result in meconium aspiration syndrome (MAS). MAS can cause respiratory complications and, very rarely, death. Antibiotics have been prescribed for neonates exposed to meconium in amniotic fluid, with the intention of preventing infection due to potential bacterial contaminants. OBJECTIVES: We conducted this review to assess the efficacy and safety of antibiotics for:1. prevention of infection, morbidity, and mortality among infants born through meconium-stained amniotic fluid (MSAF) who are asymptomatic at birth; and2. prevention of infection, morbidity, and mortality among infants born through MSAF who have signs and symptoms compatible with meconium aspiration syndrome (MAS). SEARCH METHODS: We performed a literature search using the following databases: MEDLINE (1966 to July 2016); Embase (1980 to July 2016); the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to July 2016); and the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 7) in the Cochrane Library. We also searched clinical trials databases, conference proceedings, and reference lists of retrieved articles. SELECTION CRITERIA: We included randomised and quasi-randomised controlled trials that compared antibiotics administered via any route versus placebo or no treatment for prevention of infection among neonates exposed to MSAF, or who developed MAS. We excluded cohort, case control, and any other non-randomised studies and applied no language restrictions. We included studies of term and preterm infants, and we included studies examining use of any antibacterial antibiotics. We included studies that reported on any outcomes of interest. DATA COLLECTION AND ANALYSIS: We assessed the methodological quality of included trials by reviewing information provided in study reports and obtained by personal communication with study authors. We extracted data on relevant outcomes, estimated effect size, and reported values as risk ratios (RRs), risk differences (RDs), and mean differences (MDs), as appropriate. We conducted subgroup analyses for treatment of MAS and for prophylaxis (asymptomatic neonates exposed to meconium). MAIN RESULTS: Four randomised controlled studies including a total of 695 participants were eligible for inclusion. Three studies evaluated neonates with MAS, and one study assessed asymptomatic neonates exposed to meconium in amniotic fluid. These studies exhibited varying degrees of methodological rigour: Two studies were at low risk of bias, and two were at unclear risk. We graded evidence derived from these studies as low quality. We downgraded overall evidence owing to the large number of participants lost to follow-up in one trial, the small sample sizes of all trials, and unclear methodological details provided for two trials.The primary outcome was risk of early- and late-onset neonatal sepsis. Antibiotics did not decrease the risk of sepsis in neonates with a diagnosis of MAS (RR 1.54, 95% confidence interval (CI) 0.27 to 8.96; RD 0.00, 95% CI -0.02 to 0.03; 445 participants, three studies; I² = 0%) nor in asymptomatic neonates exposed to meconium in amniotic fluid (RR 0.76, 95% CI 0.25 to 2.34; RD -0.01, 95% CI -0.07 to 0.04; 250 participants, one study; I² = 0%). Results show no significant differences in mortality or duration of stay in hospital between groups given antibiotics and control groups of symptomatic and asymptomatic neonates. One study in asymptomatic neonates reported a significant reduction in duration of mechanical ventilation for the control group compared with the antibiotic group (MD 0.26, 95% CI 0.15 to 0.37; 250 participants, one study; I² = 0%). AUTHORS' CONCLUSIONS: Upon review of available evidence, we found no differences in infection rates following antibiotic treatment among neonates born through meconium-stained fluid and those with meconium aspiration syndrome. The overall quality of evidence is low owing to the small number of included studies. Well-controlled studies of adequate power are needed.
[Mh] Termos MeSH primário: Líquido Amniótico
Antibacterianos/uso terapêutico
Infecções Bacterianas/tratamento farmacológico
Síndrome de Aspiração de Mecônio/tratamento farmacológico
Mecônio/microbiologia
Sepse Neonatal/tratamento farmacológico
[Mh] Termos MeSH secundário: Amicacina/uso terapêutico
Ampicilina/uso terapêutico
Infecções Bacterianas/mortalidade
Infecções Bacterianas/prevenção & controle
Gentamicinas/uso terapêutico
Seres Humanos
Incidência
Recém-Nascido
Tempo de Internação
Síndrome de Aspiração de Mecônio/epidemiologia
Sepse Neonatal/mortalidade
Sepse Neonatal/prevenção & controle
Ensaios Clínicos Controlados Aleatórios como Assunto
Respiração Artificial/estatística & dados numéricos
Insuficiência Respiratória/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Gentamicins); 7C782967RD (Ampicillin); 84319SGC3C (Amikacin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD006183.pub2


  6 / 12668 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28636922
[Au] Autor:Brauner A; Shoresh N; Fridman O; Balaban NQ
[Ad] Endereço:The Racah Institute of Physics and the Center for NanoScience and NanoTechnology, Edmond J. Safra Campus, The Hebrew University, Jerusalem, Israel.
[Ti] Título:An Experimental Framework for Quantifying Bacterial Tolerance.
[So] Source:Biophys J;112(12):2664-2671, 2017 Jun 20.
[Is] ISSN:1542-0086
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antibiotic tolerance and persistence are often associated with treatment failure and relapse, yet are poorly characterized. In distinction from resistance, which is measured using the minimum inhibitory concentration metric, tolerance and persistence values are not currently evaluated in the clinical setting, and so are overlooked when a course of treatment is prescribed. In this article, we introduce a metric and an automated experimental framework for measuring tolerance and persistence. The tolerance metric is the minimum duration for killing 99% of the population, MDK , which can be evaluated by a statistical analysis of measurements performed manually or using a robotic system. We demonstrate the technique on strains of Escherichia coli with various tolerance levels. We hope that this, to our knowledge, new approach will be used, along with the existing minimum inhibitory concentration, as a standard for the in vitro characterization of sensitivity to antimicrobials. Quantification of tolerance and persistence may provide vital information in healthcare, and aid research in the field.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Tolerância a Medicamentos
Testes de Sensibilidade Microbiana/métodos
[Mh] Termos MeSH secundário: Ampicilina/farmacologia
Automação Laboratorial
Escherichia coli/efeitos dos fármacos
Escherichia coli/fisiologia
Funções Verossimilhança
Robótica
Especificidade da Espécie
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 7C782967RD (Ampicillin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170823
[Lr] Data última revisão:
170823
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170622
[St] Status:MEDLINE


  7 / 12668 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28598305
[Au] Autor:Pupo I; Lepe JA; Smani Y; Aznar J
[Ad] Endereço:1​Infectious Diseases, Microbiology and Preventive Medicine Clinical Unit, University Hospital Virgen del Rocío, Seville, Spain.
[Ti] Título:Comparison of the in vitro activity of ampicillin and moxifloxacin against Listeria monocytogenes at achievable concentrations in the central nervous system.
[So] Source:J Med Microbiol;66(6):713-720, 2017 Jun.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The aim of this study was to compare the in vitro activity of ampicillin and moxifloxacin against six isolates selected from 154 invasive clinical isolates of Listeria monocytogenes and evaluate their intra- and extracellular activities with achievable central nervous system concentrations obtained using Monte Carlo simulations with conventional and unconventional dosages. METHODOLOGY: The MICs and minimal bactericidal concentrations (MBCs) of ampicillin and moxifloxacin were determined by using the broth microdilution method. The intra- and extracellular activities were compared using time-kill curves and inhibition of intracellular growth assays. RESULTS: The MICs50/90 of ampicillin were 0.125/0.5 mg l-1 and the MBC50/90 was ≥16 mg l-1, while the moxifloxacin MICs50/90 were 0.25/0.5 mg l-1 and the MBC50/90 was 0.5 mg l-1. Ampicillin did not show any extracellular bactericidal activity at 24 h, although bactericidal activity was detected at 48 h. For moxifloxacin, the bactericidal effect was evident after 6 h of incubation. Both antibiotics achieved significant reductions in intracellular inoculum after 1-24 h of incubation; however, moxifloxacin becomes bactericidal more rapidly, producing a much greater reduction in the inoculum in the first hour than ampicillin. There were no differences among the MIC and MBC values of moxifloxacin and ampicillin among the strains belonging to different serotypes and/or epidemic clones. This fact was also found in the intra- and extracellular studies. CONCLUSION: The results of this study demonstrated the faster bactericidal activity of moxifloxacin at achievable central nervous system concentrations against intra- and extracellular forms of L. monocytogenes in comparison with ampicillin.
[Mh] Termos MeSH primário: Ampicilina/farmacologia
Antibacterianos/farmacologia
Fluoroquinolonas/farmacologia
Listeria monocytogenes/efeitos dos fármacos
[Mh] Termos MeSH secundário: Células A549
Ampicilina/líquido cefalorraquidiano
Antibacterianos/líquido cefalorraquidiano
Sistema Nervoso Central
Simulação por Computador
Seres Humanos
Listeria monocytogenes/crescimento & desenvolvimento
Listeriose/microbiologia
Testes de Sensibilidade Microbiana
Método de Monte Carlo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Fluoroquinolones); 7C782967RD (Ampicillin); U188XYD42P (moxifloxacin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170610
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000486


  8 / 12668 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28542539
[Au] Autor:Lyda TA; Wagner EL; Bourg AX; Peng C; Tomaraei GN; Dean D; Kennedy MS; Marcotte WR
[Ad] Endereço:Department of Genetics and Biochemistry, Clemson University, Clemson, South Carolina, United States of America.
[Ti] Título:A Leishmania secretion system for the expression of major ampullate spidroin mimics.
[So] Source:PLoS One;12(5):e0178201, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Spider major ampullate silk fibers have been shown to display a unique combination of relatively high fracture strength and toughness compared to other fibers and show potential for tissue engineering scaffolds. While it is not possible to mass produce native spider silks, the potential ability to produce fibers from recombinant spider silk fibers could allow for an increased innovation rate within tissue engineering and regenerative medicine. In this pilot study, we improved upon a prior fabrication route by both changing the expression host and additives to the fiber pulling precursor solution to improve the performance of fibers. The new expression host for producing spidroin protein mimics, protozoan parasite Leishmania tarentolae, has numerous advantages including a relatively low cost of culture, rapid growth rate and a tractable secretion pathway. Tensile testing of hand pulled fibers produced from these spidroin-like proteins demonstrated that additives could significantly modify the fiber's mechanical and/or antimicrobial properties. Cross-linking the proteins with glutaraldehyde before fiber pulling resulted in a relative increase in tensile strength and decrease in ductility. The addition of ampicillin into the spinning solution resulted in the fibers being able to inhibit bacterial growth.
[Mh] Termos MeSH primário: Materiais Biomiméticos
Fibroínas/biossíntese
Leishmania/metabolismo
[Mh] Termos MeSH secundário: Ampicilina/farmacologia
Antibacterianos/farmacologia
Materiais Biomiméticos/farmacologia
Reatores Biológicos
Western Blotting
Reagentes para Ligações Cruzadas/química
Escherichia coli
Fibroínas/química
Fibroínas/farmacologia
Fibroínas/ultraestrutura
Glutaral/química
Leishmania/genética
Indústria Manufatureira
Teste de Materiais
Microscopia Eletrônica de Varredura
Projetos Piloto
Proteínas Recombinantes/biossíntese
Proteínas Recombinantes/química
Proteínas Recombinantes/farmacologia
Proteínas Recombinantes/ultraestrutura
Soluções
Resistência à Tração
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Cross-Linking Reagents); 0 (Recombinant Proteins); 0 (Solutions); 7C782967RD (Ampicillin); 9007-76-5 (Fibroins); T3C89M417N (Glutaral)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0178201


  9 / 12668 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28442909
[Au] Autor:Bartomeu Garcia C; Shi D; Webster TJ
[Ad] Endereço:Department of Chemical Engineering, Universitat Rovira i Virgili, Tarragona, Spain.
[Ti] Título:Tat-functionalized liposomes for the treatment of meningitis: an in vitro study.
[So] Source:Int J Nanomedicine;12:3009-3021, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Bacterial meningitis has become a global concern, because of the emergence of antibiotic-resistant bacteria. It has been demonstrated that liposomes can enter bacteria, thus providing a possible treatment for numerous infections, including meningitis. Fusogenic liposomes are pH-sensitive with a high capacity to fuse with the bacteria membrane and promote intracellular drug release. Moreover, this ability can be improved by using cell-penetrating peptides (such as Tat47-57, which is a peptide derived from the Tat protein of HIV). The purpose of this in vitro study was to demonstrate for the first time the ability of the presently prepared fusogenic liposomes, which were spherical particles with a diameter of 100 nm loaded with antibiotics and functionalized with-cell penetrating peptides (Tat ), to fight the main bacteria that cause meningitis. For this, vancomycin, methicillin, and ampicillin antibiotics were loaded inside fusogenic liposomes to fight , methicillin-resistant , and . Antibacterial activity of Tat-functionalized and nonfunctionalized liposomes loaded with antibiotics was tested by determining bacteria colony-forming units and growth-curve assays coupled with live/dead assays using fluorescence microscopy. Results showed a remarkable decrease in antibiotic minimum inhibitory concentration when all of the bacteria were treated with these novel liposomes, especially for the functionalized liposomes loaded with methicillin. With antibiotic concentrations of 1.7-3 µg/mL for Tat-functionalized liposomes loaded with methicillin, the bacteria population was totally eradicated. Cytotoxicity tests with astrocytes and endothelial cells, major cellular components of the blood-brain barrier, were also performed for all of the liposomes, including free antibiotic and the Tat peptide. Results showed much promise for the further study of the presently formulated liposomes to treat meningitis.
[Mh] Termos MeSH primário: Peptídeos Penetradores de Células/química
Lipossomos/farmacologia
Meningites Bacterianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Ampicilina/administração & dosagem
Ampicilina/farmacologia
Antibacterianos/administração & dosagem
Antibacterianos/farmacologia
Peptídeos Penetradores de Células/farmacocinética
Escherichia coli/efeitos dos fármacos
Seres Humanos
Lipossomos/química
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Testes de Sensibilidade Microbiana/métodos
Streptococcus pneumoniae/efeitos dos fármacos
Vancomicina/administração & dosagem
Vancomicina/farmacologia
Produtos do Gene tat do Vírus da Imunodeficiência Humana/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Cell-Penetrating Peptides); 0 (Liposomes); 0 (tat Gene Products, Human Immunodeficiency Virus); 6Q205EH1VU (Vancomycin); 7C782967RD (Ampicillin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S130125


  10 / 12668 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28438125
[Au] Autor:Cram ED; Rockey DD; Dolan BP
[Ad] Endereço:Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, 105 Magruder Hall, Corvallis, OR, 97331, USA. crame@oregonstate.edu.
[Ti] Título:Chlamydia spp. development is differentially altered by treatment with the LpxC inhibitor LPC-011.
[So] Source:BMC Microbiol;17(1):98, 2017 Apr 24.
[Is] ISSN:1471-2180
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chlamydia species are obligate intracellular bacteria that infect a broad range of mammalian hosts. Members of related genera are pathogens of a variety of vertebrate and invertebrate species. Despite the diversity of Chlamydia, all species contain an outer membrane lipooligosaccharide (LOS) that is comprised of a genus-conserved, and genus-defining, trisaccharide 3-deoxy-D-manno-oct-2-ulosonic acid Kdo region. Recent studies with lipopolysaccharide inhibitors demonstrate that LOS is important for the C. trachomatis developmental cycle during RB- > EB differentiation. Here, we explore the effects of one of these inhibitors, LPC-011, on the developmental cycle of five chlamydial species. RESULTS: Sensitivity to the drug varied in some of the species and was conserved between others. We observed that inhibition of LOS biosynthesis in some chlamydial species induced formation of aberrant reticulate bodies, while in other species, no change was observed to the reticulate body. However, loss of LOS production prevented completion of the chlamydial reproductive cycle in all species tested. In previous studies we found that C. trachomatis and C. caviae infection enhances MHC class I antigen presentation of a model self-peptide. We find that treatment with LPC-011 prevents enhanced host-peptide presentation induced by infection with all chlamydial-species tested. CONCLUSIONS: The data demonstrate that LOS synthesis is necessary for production of infectious progeny and inhibition of LOS synthesis induces aberrancy in certain chlamydial species, which has important implications for the use of LOS synthesis inhibitors as potential antibiotics.
[Mh] Termos MeSH primário: Proteínas de Bactérias/efeitos dos fármacos
Proteínas de Bactérias/genética
Chlamydia/efeitos dos fármacos
Chlamydia/crescimento & desenvolvimento
Ácidos Hidroxâmicos/antagonistas & inibidores
Treonina/análogos & derivados
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Ampicilina/farmacologia
Animais
Antibacterianos/farmacologia
Linhagem Celular/efeitos dos fármacos
Linhagem Celular/microbiologia
Chlamydia/genética
Chlamydia/patogenicidade
Infecções por Chlamydia/tratamento farmacológico
Citoplasma/microbiologia
Fibroblastos
Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos
Interações Hospedeiro-Patógeno
Seres Humanos
Ácidos Hidroxâmicos/administração & dosagem
Lipopolissacarídeos/biossíntese
Camundongos
Testes de Sensibilidade Microbiana
Fenótipo
Filogenia
Biossíntese de Proteínas/efeitos dos fármacos
Alinhamento de Sequência
Análise de Sequência de Proteína
Açúcares Ácidos
Treonina/administração & dosagem
Treonina/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Hydroxamic Acids); 0 (LPC-011); 0 (Lipopolysaccharides); 0 (Sugar Acids); 0 (lipid-linked oligosaccharides); 1069-03-0 (2-keto-3-deoxyoctonate); 2ZD004190S (Threonine); 7C782967RD (Ampicillin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE
[do] DOI:10.1186/s12866-017-0992-8



página 1 de 1267 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde